Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Moleculin Biotech Inc | MBRX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.60 | 04:54:31 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.60 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.28 - 15.75 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 4.60 | USD |
Moleculin Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 153.7M | 33.41M | - | 0 | -29.77M | -0.89 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Moleculin Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MBRX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.32 | 5.00 | 4.28 | 4.48 | 18,961 | 0.28 | 6.48% |
| 1 Month | 4.80 | 6.2348 | 4.28 | 5.17 | 31,513 | -0.20 | -4.17% |
| 3 Months | 7.47 | 10.35 | 4.28 | 7.18 | 115,802 | -2.87 | -38.42% |
| 6 Months | 7.146 | 15.75 | 4.28 | 8.60 | 150,669 | -2.55 | -35.63% |
| 1 Year | 11.70 | 15.75 | 4.28 | 8.88 | 154,314 | -7.10 | -60.68% |
| 3 Years | 52.2345 | 59.85 | 4.28 | 24.75 | 163,094 | -47.63 | -91.19% |
| 5 Years | 24.60 | 131.70 | 4.28 | 26.58 | 999,553 | -20.00 | -81.30% |
Moleculin Biotech Description
| Moleculin Biotech Inc is a clinical-stage pharmaceutical company with a focus on the treatment of highly resistant cancers and viruses through the development of its drug candidates. The company has three core technologies: Annamycin which is a next-generation anthracycline; Immune/Transcription Modulators, of which WP1066 is a member; and Metabolism/Glycosylation Inhibitors, of which WP1122 is a member. |
